IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PUOTI, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.702
EU - Europa 2.107
AS - Asia 2.057
SA - Sud America 222
AF - Africa 20
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 13
Totale 10.138
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.665
CN - Cina 902
UA - Ucraina 741
SG - Singapore 539
DE - Germania 390
HK - Hong Kong 348
FI - Finlandia 207
BR - Brasile 200
IT - Italia 175
GB - Regno Unito 127
TR - Turchia 119
RU - Federazione Russa 115
IE - Irlanda 113
PL - Polonia 101
IN - India 84
FR - Francia 47
SE - Svezia 30
CA - Canada 28
BE - Belgio 16
AU - Australia 13
EU - Europa 13
IR - Iran 9
NL - Olanda 9
AR - Argentina 8
JP - Giappone 8
ZA - Sudafrica 8
AT - Austria 7
BD - Bangladesh 7
AE - Emirati Arabi Uniti 4
IQ - Iraq 4
MU - Mauritius 4
MX - Messico 4
NZ - Nuova Zelanda 4
SA - Arabia Saudita 4
CZ - Repubblica Ceca 3
EC - Ecuador 3
ES - Italia 3
IL - Israele 3
LA - Repubblica Popolare Democratica del Laos 3
LT - Lituania 3
MA - Marocco 3
PK - Pakistan 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
VN - Vietnam 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
ID - Indonesia 2
KZ - Kazakistan 2
LB - Libano 2
PA - Panama 2
PE - Perù 2
RS - Serbia 2
TN - Tunisia 2
UZ - Uzbekistan 2
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GT - Guatemala 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LR - Liberia 1
LV - Lettonia 1
NO - Norvegia 1
PH - Filippine 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
TM - Turkmenistan 1
UY - Uruguay 1
Totale 10.138
Salva come PNG Salva come JPEG
Città #
Woodbridge 766
Fairfield 665
Jacksonville 553
Houston 479
Ashburn 463
Singapore 391
Hong Kong 348
Ann Arbor 336
Wilmington 335
Cambridge 310
Seattle 299
Nanjing 227
Princeton 193
Chandler 177
Beijing 141
Dublin 113
Istanbul 101
Warsaw 101
Helsinki 92
Nanchang 89
Dearborn 80
Moscow 69
New York 67
Shenyang 59
Des Moines 53
The Dalles 47
San Diego 46
Changsha 43
Tianjin 42
Hebei 41
Shanghai 38
Jiaxing 36
Jinan 36
Los Angeles 34
Milan 33
Lancaster 32
Brescia 30
Washington 28
London 27
Munich 27
Verona 21
Kunming 19
San Francisco 18
Brussels 16
Taizhou 16
Toronto 16
Hangzhou 15
Kocaeli 15
São Paulo 15
Zhengzhou 15
Lanzhou 14
Leawood 13
San Mateo 13
Haikou 11
Monmouth Junction 11
Norwalk 11
Augusta 9
Ningbo 9
Ardabil 8
Charlotte 8
Melbourne 8
Rio de Janeiro 8
Tokyo 8
Belo Horizonte 7
Brasília 7
Brooklyn 7
Guangzhou 7
Turku 7
Orange 6
Taiyuan 6
Fuzhou 5
Hefei 5
Nuremberg 5
Auckland 4
Porto Alegre 4
Ribeirão Preto 4
Rome 4
Santa Clara 4
Sydney 4
Boardman 3
Boston 3
Bratislava 3
Caruaru 3
Caxias do Sul 3
Chennai 3
Chicago 3
Curitiba 3
Delhi 3
Goiânia 3
Grafing 3
Guarulhos 3
Gunzenhausen 3
Kilburn 3
Messina 3
Ottawa 3
Quito 3
Rende 3
Secaucus 3
Vienna 3
Vientiane 3
Totale 7.493
Salva come PNG Salva come JPEG
Nome #
Use of brain MRI in manganese exposure 165
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients 157
Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial 148
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis 140
A meta-analysis of epidemiological studies on the combined effect of hepatitis-B and -C virus infections in causing hepatocellular carcinoma. 138
Antiretroviral drugs and liver injury. 138
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 132
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 132
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. 130
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 127
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. 127
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 125
Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and Human Immunodeficiency Virus. 125
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 124
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 123
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. 120
Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. 118
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel 116
Polymorphic immune restoration syndrome after effective HAART 115
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 114
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis. 113
Mortality for liver disease in patients with HIV infection: a cohort study 111
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 111
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. 109
Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. 107
Care of patients with hepatitis C and HIV co-infection. 107
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. 105
Coinfezione HIV/HBV in Burkina Faso, Africa Occidentalele 104
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. 104
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. 104
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C?A gender-oriented analysis. 104
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 103
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. 102
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study 101
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 101
Clinical presentation and outcome of hepatocellular carcinoma in HIV infected patients. 100
Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? 100
Statements from the Taormina expert meeting on occult hepatitis B virus infection. 100
Hepatitis B Virus Co-infection in Human Immunodeficiency Virus- infected Subjects 99
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 98
Natural history of chronic hepatitis B in co-infected patients. 98
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 97
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 97
The burden of HIV and hepatitis C virus coinfection. 97
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia 97
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 96
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: risultati del primo anno di attività. 95
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 95
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. 95
HCV chronic hepatitis in patients with HIV: clinical management issues 94
The use of molecular assays in the management of viral hepatitis. 94
Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV 94
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 93
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. 93
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? 93
Management of hepatitis C in human immunodeficiency virus-infected patients. 92
Impact of hepatitis C virus infection on lifestyle. 91
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. 91
Studio di coorte multicentrico per l'analisi dei fattori che influenzano la risposta alla terapia antivirale in pazienti HCV positivi: disegno dello studio. 90
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 90
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 90
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. 90
The attributable risk of hepatocarcinoma for the Hepatitis B and C virus infections in a high-incidence area in North Italy: a case-control study. 89
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 89
HIV/HCV co-infection: natural history. 88
The T-cell receptor repertoires expressed by CD4+ and CD4- large granularlymphocytes derived from the same patients suggest the persistent action of animmune-mediated selection process 88
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. 87
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. 87
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 86
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? 85
Comment to the Editorial: Liver biopsy in HIV-infected pateints with chronic hepatitis C: pros and cons, by V. Soriano and J. Garcia Samaniego 84
Studio di affidabilità sul consumo di alcol, caffè e abitudine al fumo in pazienti HCV postivi. 84
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. 83
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? 82
Co-infezione HIV-HCV e dislipidemie in corso di Highly Active Antiretroviral Therapy (HAART) 82
Hepatitis viruses coinfections, antiretrovirals hepatotoxicity and risk of death in HIV infected patients: a prospective cohort study 81
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 80
Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy 80
Ruolo dell'infezione occulta da virus dell'epatite B nell'evoluzione dell'epatite cronica da virus C attraverso uno studio di coorte multicentrico: dati preliminari. 78
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 78
Targeted screening for viral epatiti in an italian community of 100.000 inhabitants 77
Insulin resistance is not a relevant predictor of sustaned virologic response (SVR) in chronic hepatitis c (CHC) patients treated with pegylated interferon (peg-ifn) and ribavirin. 77
Insulino-resistenza in pazienti HCV positivi sottoposti a trattamento antivirale in uno studio di coorte multicentrico: dati preliminari. 77
Indagine sulla suscettibilità genetica nella risposta al trattamento antivirale di soggetti con epatite cronica da virus c attraverso uno studio di coorte multicentrico: disegno dello studio. 77
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection-statements of the First Italian Consensus Workshop. 76
Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology) 76
Co-infezione HIV-HCV e dislipidemie in corso di terapia antiretrovirale ad elevata efficacia (HAART) 73
Hepatotoxicity associated with non nucleoside reverse trasciptase inhibitors (NNRTI) in 427 adults infected with Human Immunodeficiency Virus. 72
I Data-Base clinici e la sorveglianza degli eventi avversi alla HAART: il Progetto MASTER 68
HCV infection: pathogenesis, clinical manifestations and therapy. 68
Occult Hepatitis B virus and hepatocellular carcinoma: a case-control study. 68
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome 66
Pathogenesis of liver damage in HCV-HIV patients. 65
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 65
Hepatitis C viral kinetics in HIV co-infected patients during combination treatment with interferon and ribavirin 63
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3 63
Risk of developing specific AIDS-defining illnesses in patients coinfected withHIV and hepatitis C virus with or without liver cirrhosis 63
Prevalence des marqueurs du virus de l'hepatite B et des anticorps contre le virus de l'hepatite C parmi le personnel du District sanitaire de Nanoro, Burkina Faso 61
Stima della prevalenza di malattie epatiche e della loro eziologia in un'area ad alta incidenza mediante utilizzo di dati correnti. 60
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 60
Totale 9.645
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.931
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.931
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020152 0 0 0 0 0 0 0 0 0 0 0 152
2020/20211.463 17 165 32 224 51 149 82 155 244 110 196 38
2021/2022834 52 128 1 46 3 46 40 55 35 119 86 223
2022/2023654 112 8 10 31 49 207 0 70 90 7 31 39
2023/2024786 42 16 71 81 45 141 31 36 199 14 2 108
2024/20251.671 8 4 7 237 213 158 156 39 150 148 372 179
Totale 10.243